Crism Therapeutics: Grant of Options
30 June 2026
CRISM Therapeutics Corporation
('CRISM', 'CRISM Therapeutics' or the 'Company')
Grant of Options
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has granted options over ordinary shares of no par value ('Ordinary Shares') in the Company (the 'Options') on 30 June 2026 to certain directors as set out below.
Director
Total number of Ordinary Shares subject to option grant
Options
exercise price
Vesting
Period
Andrew Webb
504,000
10p
30 June 2026 - 30 June 2028
Chris McConville
408,798
10p
30 June 2026 - 30 June 2028
Gerry Beaney
99,999
10p
30 June 2026 - 30 June 2028
The awards have been made under the Company's existing EMI Share Option Plan. The Options will vest as to one-third on grant, one-third on the first anniversary of grant and one-third on the second anniversary of grant. The options will become exercisable on the second anniversary of grant and expire on 30 June 2036, being 10 years from the date of grant.
The grant of Options to the Executive directors was overseen by the Remuneration Committee which made recommendations to the Board based on its assessment of each executive's personal performance during 2025 and 2026.
- Ends -
Enquiries:
Company
Nomad and Broker
Financial PR
CRISM Therapeutics Corporation
S.P. Angel Corporate Finance LLP
Burson Buchanan
Andrew Webb, Executive Chairman
Chris McConville, CSO
David Hignell
Vadim Alexandre
Adam Cowl
Henry Harrison Topham
Jamie Hooper
CRISM@buchanancomms.co.uk
via Burson Buchanan
+44 (0) 20 3470 0470
+44 (0) 20 7466 5000
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
For more information please visit: https://www.crismtherapeutics.com/
The Company's LEI is 213800XFW6MKVCHHPW88.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
1) Andrew Webb
2) Gerald Beaney
3) Chris McConville
2
Reason for the notification
a)
Position/status
1) Executive Chairman
2) Non-Executive Director
3) Chief Scientific Officer
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
CRISM Therapeutics Corporation
b)
LEI
213800XFW6MKVCHHPW88
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares with no par value
Identification code
ISIN: VGG042401262
b)
Nature of the transaction
Grant of Options
c)
Price(s) and volume(s)
Director/PDMR
Exercise Price
Volume
Andrew Webb
£0.10
504,000
Gerald Beaney
£0.10
99,999
Chris McConville
£0.10
408,798
d)
Aggregated information
- Aggregated volume
N/A
- Price
N/A
e)
Date of the transaction
30 June 2026
f)
Place of the transaction
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHZBLFXQQLLBBX
